Niteesh K Choudhry Selected Research

Secondary Prevention

1/2020	Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial.
5/2014	Eliminating medication copayments reduces disparities in cardiovascular care.
4/2013	The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review.
10/2012	The impact of reducing cardiovascular medication copayments on health spending and resource utilization.
10/2011	Variation in initiating secondary prevention after myocardial infarction by hospitals and physicians, 1997 through 2004.
11/2009	Costs and benefits of free medications after myocardial infarction.
12/2008	Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients.
3/2008	Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries.
1/2007	Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Niteesh K Choudhry Research Topics

Disease

22	Myocardial Infarction 01/2020 - 01/2007
14	Atrial Fibrillation 11/2018 - 01/2006
11	Stroke (Strokes) 11/2021 - 01/2006
11	Cardiovascular Diseases (Cardiovascular Disease) 01/2019 - 11/2006
10	Hemorrhage 01/2018 - 01/2006
7	Hypertension (High Blood Pressure) 01/2023 - 12/2010
7	Coronary Artery Disease (Coronary Atherosclerosis) 04/2013 - 10/2007
6	Heart Failure 01/2024 - 07/2006
6	Type 2 Diabetes Mellitus (MODY) 01/2020 - 09/2012
6	Acute Coronary Syndrome 09/2014 - 08/2007
5	Pain (Aches) 12/2022 - 01/2016
5	Chronic Disease (Chronic Diseases) 01/2017 - 07/2011
4	Chronic Limb-Threatening Ischemia 04/2024 - 01/2016
4	Diabetes Mellitus 11/2018 - 10/2007
4	Hyperlipidemias (Hyperlipidemia) 05/2018 - 04/2009
3	Hypoglycemia (Reactive Hypoglycemia) 12/2014 - 09/2012
3	Coronary Disease (Coronary Heart Disease) 02/2014 - 11/2006
3	Vascular Diseases (Vascular Disease) 10/2012 - 04/2008
2	Acute Kidney Injury (Acute Renal Failure) 01/2023 - 12/2012
2	Back Pain (Backache) 12/2021 - 01/2016
2	Unstable Angina 10/2018 - 05/2005
2	Pulmonary Embolism 01/2018 - 05/2012
2	Cerebral Hemorrhage 01/2018 - 07/2006
2	Venous Thrombosis (Deep-Vein Thrombosis) 01/2018 - 05/2012
2	Confusion (Bewilderment) 12/2014 - 02/2013
2	Infarction (Infarctions) 06/2009 - 05/2005
2	Osteoporosis 02/2008 - 05/2006
1	COVID-19 11/2023
1	Bradycardia 01/2023
1	Hypotension (Low Blood Pressure) 01/2023
1	Hyperkalemia 01/2023
1	Gout 11/2021
1	Herpes Zoster 09/2019
1	Multiple Sclerosis 01/2019
1	Headache (Headaches) 01/2018
1	Seizures (Absence Seizure) 10/2016
1	Drug-Related Side Effects and Adverse Reactions 10/2016
1	Cocaine-Related Disorders (Cocaine Addiction) 01/2016
1	Migraine Disorders (Migraine) 01/2016
1	Postoperative Pain 01/2016

Drug/Important Bio-Agent (IBA)

20	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 05/2018 - 11/2006
11	Warfarin (Coumadin)FDA LinkGeneric 11/2018 - 01/2006
9	Clopidogrel (Plavix)FDA Link 01/2019 - 04/2008
8	Prescription DrugsIBA 07/2015 - 03/2008
7	Insulin (Novolin)FDA Link 01/2020 - 09/2012
7	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2017 - 01/2006
6	AnticoagulantsIBA 01/2019 - 07/2012
4	Dabigatran FDA Link 11/2018 - 07/2012
4	Opioid Analgesics (Opioids)IBA 01/2018 - 01/2016
4	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 05/2014 - 01/2007
4	Angiotensin Receptor AntagonistsIBA 09/2012 - 03/2008
3	apixabanIBA 01/2018 - 07/2012
3	Antidepressive Agents (Antidepressants)IBA 01/2017 - 11/2015
3	Generic DrugsIBA 07/2014 - 12/2008
2	VaccinesIBA 11/2023 - 09/2019
2	IceIBA 12/2022 - 12/2021
2	Antihypertensive Agents (Antihypertensives)IBA 11/2021 - 01/2018
2	Hemoglobins (Hemoglobin)IBA 01/2020 - 06/2005
2	CholesterolIBA 11/2018 - 11/2010
2	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 04/2017 - 11/2015
2	RivaroxabanIBA 11/2014 - 07/2012
2	Proton Pump InhibitorsIBA 09/2013 - 12/2009
2	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 09/2013 - 04/2008
2	AngiotensinsIBA 09/2012 - 10/2011
1	Cholinergic Antagonists (Anticholinergics)IBA 01/2024
1	Uric Acid (Urate)IBA 11/2021
1	Fingolimod Hydrochloride (FTY720)FDA Link 01/2019
1	omega-Chloroacetophenone (Mace)IBA 01/2019
1	Dimethyl FumarateIBA 01/2019
1	TicagrelorIBA 01/2019
1	Metoprolol (Toprol-XL)FDA LinkGeneric 10/2018
1	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 01/2018
1	edoxabanIBA 01/2018
1	Amiodarone (Amiodarona)FDA LinkGeneric 01/2018
1	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 01/2018
1	Digoxin (Digitek)FDA LinkGeneric 01/2018
1	MagnesiumIBA 01/2018
1	Fluvoxamine (Luvox)FDA LinkGeneric 04/2017
1	Cytochrome P-450 CYP2C9 InhibitorsIBA 04/2017
1	Fluoxetine (Prozac)FDA LinkGeneric 04/2017
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2017
1	Sodium Chloride Symporter Inhibitors (Diuretics, Thiazide)IBA 01/2017
1	TabletsIBA 01/2017
1	Oxycodone (Oxycontin)FDA LinkGeneric 01/2017
1	Anticonvulsants (Antiepileptic Drugs)IBA 10/2016
1	Methotrexate (Mexate)FDA LinkGeneric 01/2016

Therapy/Procedure

37	Therapeutics 04/2024 - 05/2006
9	Secondary Prevention 01/2020 - 01/2007
6	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 11/2015 - 10/2007
6	Drug Therapy (Chemotherapy) 05/2015 - 01/2007
3	Aftercare (After-Treatment) 01/2023 - 01/2016
3	Glycemic Control 01/2020 - 09/2012
3	Patient Readmission 10/2018 - 05/2005
3	Percutaneous Coronary Intervention 11/2013 - 04/2008
2	Renal Dialysis (Hemodialysis) 05/2012 - 11/2011
1	Length of Stay 01/2023
1	Surgical Amputation (Amputations) 12/2022
1	Physical Therapy Modalities (Physical Therapy Technique) 12/2022
1	Polypharmacy 01/2021
1	Medication Reconciliation 10/2016